#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4.
1-1	0-2	4.	_	_	_	_

#Text=Discussion
2-1	3-13	Discussion	abstract	new	_	_

#Text=In the present study , the absorption pattern and pharmacokinetic pattern of free choline from Superba Boost TM krill oil and choline bitartrate were investigated .
3-1	14-16	In	_	_	_	_
3-2	17-20	the	abstract[2]	new[2]	coref	9-25[74_2]
3-3	21-28	present	abstract[2]	new[2]	_	_
3-4	29-34	study	abstract[2]	new[2]	_	_
3-5	35-36	,	_	_	_	_
3-6	37-40	the	abstract[4]	new[4]	_	_
3-7	41-51	absorption	abstract|abstract[4]	new|new[4]	_	_
3-8	52-59	pattern	abstract[4]	new[4]	_	_
3-9	60-63	and	_	_	_	_
3-10	64-79	pharmacokinetic	abstract|abstract[6]	new|new[6]	coref|coref	22-41|22-41
3-11	80-87	pattern	abstract[6]	new[6]	_	_
3-12	88-90	of	abstract[6]	new[6]	_	_
3-13	91-95	free	abstract[6]|substance[7]	new[6]|new[7]	coref	4-6[0_7]
3-14	96-103	choline	abstract[6]|substance[7]	new[6]|new[7]	_	_
3-15	104-108	from	abstract[6]|substance[7]	new[6]|new[7]	_	_
3-16	109-116	Superba	abstract[6]|substance[7]|substance	new[6]|new[7]|new	coref	4-2
3-17	117-122	Boost	abstract[6]|substance[7]	new[6]|new[7]	_	_
3-18	123-125	TM	abstract[6]|substance[7]|object|substance[11]	new[6]|new[7]|new|new[11]	coref|coref|coref|coref	4-2[16_0]|16-22[163_11]|4-2[16_0]|16-22[163_11]
3-19	126-131	krill	abstract[6]|substance[7]|abstract|substance[11]	new[6]|new[7]|new|new[11]	coref	20-1
3-20	132-135	oil	abstract[6]|substance[7]|substance[11]	new[6]|new[7]|new[11]	_	_
3-21	136-139	and	abstract[6]|substance[7]	new[6]|new[7]	_	_
3-22	140-147	choline	abstract[6]|substance[7]|abstract|substance[13]	new[6]|new[7]|new|new[13]	coref|coref|coref|coref	4-26[22_13]|8-5|4-26[22_13]|8-5
3-23	148-158	bitartrate	abstract[6]|substance[7]|substance[13]	new[6]|new[7]|new[13]	_	_
3-24	159-163	were	_	_	_	_
3-25	164-176	investigated	_	_	_	_
3-26	177-178	.	_	_	_	_

#Text=In Superba Boost TM , choline is bound in a lipid-soluble form as phosphatidylcholine , while it is present as a water-soluble salt structure in choline bitartrate .
4-1	179-181	In	_	_	_	_
4-2	182-189	Superba	substance|abstract[15]|object[16]	giv|new[15]|giv[16]	ana|coref|coref|ana|coref|coref|ana|coref|coref	4-17[0_16]|5-12|5-12[28_15]|4-17[0_16]|5-12|5-12[28_15]|4-17[0_16]|5-12|5-12[28_15]
4-3	190-195	Boost	abstract[15]|object[16]	new[15]|giv[16]	_	_
4-4	196-198	TM	object[16]	giv[16]	_	_
4-5	199-200	,	_	_	_	_
4-6	201-208	choline	substance	giv	coref	4-26
4-7	209-211	is	_	_	_	_
4-8	212-217	bound	_	_	_	_
4-9	218-220	in	_	_	_	_
4-10	221-222	a	substance[18]	new[18]	_	_
4-11	223-236	lipid-soluble	substance[18]	new[18]	_	_
4-12	237-241	form	substance[18]	new[18]	_	_
4-13	242-244	as	substance[18]	new[18]	_	_
4-14	245-264	phosphatidylcholine	substance[18]	new[18]	_	_
4-15	265-266	,	_	_	_	_
4-16	267-272	while	_	_	_	_
4-17	273-275	it	object	giv	coref	5-14
4-18	276-278	is	_	_	_	_
4-19	279-286	present	_	_	_	_
4-20	287-289	as	_	_	_	_
4-21	290-291	a	_	_	_	_
4-22	292-305	water-soluble	_	_	_	_
4-23	306-310	salt	substance	new	_	_
4-24	311-320	structure	_	_	_	_
4-25	321-323	in	_	_	_	_
4-26	324-331	choline	substance|substance[22]	giv|giv[22]	coref|coref|coref|coref	5-5|5-16[31_22]|5-5|5-16[31_22]
4-27	332-342	bitartrate	substance[22]	giv[22]	_	_
4-28	343-344	.	_	_	_	_

#Text=Results show that free choline levels in plasma were comparable between Superba Boost TM and choline bitartrate , but peak choline concentrations were reached significantly later upon intake of Superba Boost TM compared to choline bitartrate .
5-1	345-352	Results	abstract	new	_	_
5-2	353-357	show	_	_	_	_
5-3	358-362	that	_	_	_	_
5-4	363-367	free	abstract[25]	new[25]	coref	6-3[40_25]
5-5	368-375	choline	substance|abstract[25]	giv|new[25]	coref	5-16
5-6	376-382	levels	abstract[25]	new[25]	_	_
5-7	383-385	in	abstract[25]	new[25]	_	_
5-8	386-392	plasma	abstract[25]|substance	new[25]|new	coref	12-40
5-9	393-397	were	_	_	_	_
5-10	398-408	comparable	_	_	_	_
5-11	409-416	between	_	_	_	_
5-12	417-424	Superba	organization|abstract[28]	giv|giv[28]	coref|coref|coref|coref	5-30|5-30[36_28]|5-30|5-30[36_28]
5-13	425-430	Boost	abstract[28]	giv[28]	_	_
5-14	431-433	TM	abstract[28]|abstract	giv[28]|giv	coref	5-30[37_0]
5-15	434-437	and	abstract[28]	giv[28]	_	_
5-16	438-445	choline	abstract[28]|substance|substance[31]	giv[28]|giv|giv[31]	coref|coref|coref|coref	5-21|5-35[39_31]|5-21|5-35[39_31]
5-17	446-456	bitartrate	abstract[28]|substance[31]	giv[28]|giv[31]	_	_
5-18	457-458	,	_	_	_	_
5-19	459-462	but	_	_	_	_
5-20	463-467	peak	animal[33]	new[33]	coref	8-3[63_33]
5-21	468-475	choline	substance|animal[33]	giv|new[33]	coref	5-35
5-22	476-490	concentrations	animal[33]	new[33]	_	_
5-23	491-495	were	_	_	_	_
5-24	496-503	reached	_	_	_	_
5-25	504-517	significantly	_	_	_	_
5-26	518-523	later	_	_	_	_
5-27	524-528	upon	_	_	_	_
5-28	529-535	intake	event[34]	new[34]	coref	6-21[47_34]
5-29	536-538	of	event[34]	new[34]	_	_
5-30	539-546	Superba	event[34]|organization|abstract[36]|substance[37]	new[34]|giv|giv[36]|giv[37]	coref|coref|coref|coref|coref|coref|coref|coref|coref	6-23|6-23[49_36]|6-23[50_37]|6-23|6-23[49_36]|6-23[50_37]|6-23|6-23[49_36]|6-23[50_37]
5-31	547-552	Boost	event[34]|abstract[36]|substance[37]	new[34]|giv[36]|giv[37]	_	_
5-32	553-555	TM	event[34]|substance[37]	new[34]|giv[37]	_	_
5-33	556-564	compared	_	_	_	_
5-34	565-567	to	_	_	_	_
5-35	568-575	choline	substance|substance[39]	giv|giv[39]	coref|coref|coref|coref	6-6|6-28[52_39]|6-6|6-28[52_39]
5-36	576-586	bitartrate	substance[39]	giv[39]	_	_
5-37	587-588	.	_	_	_	_

#Text=Moreover , levels of the choline metabolites betaine and DMG were higher , while levels of TMAO were lower upon intake of Superba Boost TM compared to choline bitartrate .
6-1	589-597	Moreover	_	_	_	_
6-2	598-599	,	_	_	_	_
6-3	600-606	levels	abstract[40]	giv[40]	coref	6-15[45_40]
6-4	607-609	of	abstract[40]	giv[40]	_	_
6-5	610-613	the	abstract[40]|substance[42]|substance[43]	giv[40]|new[42]|new[43]	coref|coref	7-13[59_42]|7-13[59_42]
6-6	614-621	choline	abstract[40]|substance|substance[42]|substance[43]	giv[40]|giv|new[42]|new[43]	coref	6-28
6-7	622-633	metabolites	abstract[40]|substance[42]|substance[43]	giv[40]|new[42]|new[43]	_	_
6-8	634-641	betaine	abstract[40]|substance[43]	giv[40]|new[43]	_	_
6-9	642-645	and	abstract[40]	giv[40]	_	_
6-10	646-649	DMG	abstract[40]|person	giv[40]|new	_	_
6-11	650-654	were	_	_	_	_
6-12	655-661	higher	_	_	_	_
6-13	662-663	,	_	_	_	_
6-14	664-669	while	_	_	_	_
6-15	670-676	levels	abstract[45]	giv[45]	_	_
6-16	677-679	of	abstract[45]	giv[45]	_	_
6-17	680-684	TMAO	abstract[45]|abstract	giv[45]|new	_	_
6-18	685-689	were	_	_	_	_
6-19	690-695	lower	_	_	_	_
6-20	696-700	upon	_	_	_	_
6-21	701-707	intake	event[47]	giv[47]	coref	7-4[55_47]
6-22	708-710	of	event[47]	giv[47]	_	_
6-23	711-718	Superba	event[47]|substance|abstract[49]|substance[50]	giv[47]|giv|giv[49]|giv[50]	coref|coref|coref|coref|coref|coref|coref|coref|coref	13-41|13-43[0_50]|14-21[144_49]|13-41|13-43[0_50]|14-21[144_49]|13-41|13-43[0_50]|14-21[144_49]
6-24	719-724	Boost	event[47]|abstract[49]|substance[50]	giv[47]|giv[49]|giv[50]	_	_
6-25	725-727	TM	event[47]|substance[50]	giv[47]|giv[50]	_	_
6-26	728-736	compared	_	_	_	_
6-27	737-739	to	_	_	_	_
6-28	740-747	choline	substance|substance[52]	giv|giv[52]	coref|coref|coref|coref	7-4|13-35[122_52]|7-4|13-35[122_52]
6-29	748-758	bitartrate	substance[52]	giv[52]	_	_
6-30	759-760	.	_	_	_	_

#Text=The dependency between choline intake and circulating levels of free choline and its metabolites is concealed by homeostatic regulations and rapid tissue uptake .
7-1	761-764	The	abstract[53]	new[53]	_	_
7-2	765-775	dependency	abstract[53]	new[53]	_	_
7-3	776-783	between	abstract[53]	new[53]	_	_
7-4	784-791	choline	abstract[53]|substance|event[55]	new[53]|giv|giv[55]	coref|coref|coref|coref	7-10[57_0]|9-37[79_55]|7-10[57_0]|9-37[79_55]
7-5	792-798	intake	abstract[53]|event[55]	new[53]|giv[55]	_	_
7-6	799-802	and	_	_	_	_
7-7	803-814	circulating	abstract[56]	new[56]	coref	9-5[70_56]
7-8	815-821	levels	abstract[56]	new[56]	_	_
7-9	822-824	of	abstract[56]	new[56]	_	_
7-10	825-829	free	abstract[56]|substance[57]	new[56]|giv[57]	ana	7-13[0_57]
7-11	830-837	choline	abstract[56]|substance[57]	new[56]|giv[57]	_	_
7-12	838-841	and	abstract[56]	new[56]	_	_
7-13	842-845	its	abstract[56]|substance|substance[59]	new[56]|giv|giv[59]	coref|coref	8-7[66_59]|8-7[66_59]
7-14	846-857	metabolites	abstract[56]|substance[59]	new[56]|giv[59]	_	_
7-15	858-860	is	_	_	_	_
7-16	861-870	concealed	_	_	_	_
7-17	871-873	by	_	_	_	_
7-18	874-885	homeostatic	abstract[60]	new[60]	_	_
7-19	886-897	regulations	abstract[60]	new[60]	_	_
7-20	898-901	and	_	_	_	_
7-21	902-907	rapid	abstract[62]	new[62]	coref	25-4[0_62]
7-22	908-914	tissue	object|abstract[62]	new|new[62]	_	_
7-23	915-921	uptake	abstract[62]	new[62]	_	_
7-24	922-923	.	_	_	_	_

#Text=Thus , concentrations of choline and its metabolites are usually within a narrow range .
8-1	924-928	Thus	_	_	_	_
8-2	929-930	,	_	_	_	_
8-3	931-945	concentrations	animal[63]	giv[63]	_	_
8-4	946-948	of	animal[63]	giv[63]	_	_
8-5	949-956	choline	animal[63]|substance	giv[63]|giv	ana	8-7
8-6	957-960	and	animal[63]	giv[63]	_	_
8-7	961-964	its	animal[63]|substance|substance[66]	giv[63]|giv|giv[66]	coref|coref	9-8|9-8
8-8	965-976	metabolites	animal[63]|substance[66]	giv[63]|giv[66]	_	_
8-9	977-980	are	_	_	_	_
8-10	981-988	usually	abstract[67]	new[67]	_	_
8-11	989-995	within	abstract[67]	new[67]	_	_
8-12	996-997	a	abstract[67]	new[67]	_	_
8-13	998-1004	narrow	abstract[67]	new[67]	_	_
8-14	1005-1010	range	abstract[67]	new[67]	_	_
8-15	1011-1012	.	_	_	_	_

#Text=In the literature , endogenous free fasting choline levels under physiological conditions range between 7 – 12 µmol/L , which could be confirmed in the present study with a mean choline concentration of 9.6 µmol/L before product intake .
9-1	1013-1015	In	_	_	_	_
9-2	1016-1019	the	abstract[68]	new[68]	_	_
9-3	1020-1030	literature	abstract[68]	new[68]	_	_
9-4	1031-1032	,	_	_	_	_
9-5	1033-1043	endogenous	abstract[70]	giv[70]	coref	11-6[86_70]
9-6	1044-1048	free	abstract[70]	giv[70]	_	_
9-7	1049-1056	fasting	abstract[70]	giv[70]	_	_
9-8	1057-1064	choline	substance|abstract[70]	giv|giv[70]	coref	9-31
9-9	1065-1071	levels	abstract[70]	giv[70]	_	_
9-10	1072-1077	under	abstract[70]	giv[70]	_	_
9-11	1078-1091	physiological	abstract[70]|abstract[71]	giv[70]|new[71]	_	_
9-12	1092-1102	conditions	abstract[70]|abstract[71]	giv[70]|new[71]	_	_
9-13	1103-1108	range	_	_	_	_
9-14	1109-1116	between	_	_	_	_
9-15	1117-1118	7	quantity[73]	new[73]	_	_
9-16	1119-1120	–	quantity[73]	new[73]	_	_
9-17	1121-1123	12	quantity|quantity[73]	new|new[73]	coref	28-36
9-18	1124-1130	µmol/L	quantity[73]	new[73]	_	_
9-19	1131-1132	,	_	_	_	_
9-20	1133-1138	which	_	_	_	_
9-21	1139-1144	could	_	_	_	_
9-22	1145-1147	be	_	_	_	_
9-23	1148-1157	confirmed	_	_	_	_
9-24	1158-1160	in	_	_	_	_
9-25	1161-1164	the	abstract[74]	giv[74]	ana	11-1[0_74]
9-26	1165-1172	present	abstract[74]	giv[74]	_	_
9-27	1173-1178	study	abstract[74]	giv[74]	_	_
9-28	1179-1183	with	abstract[74]	giv[74]	_	_
9-29	1184-1185	a	abstract[74]|quantity[76]	giv[74]|new[76]	_	_
9-30	1186-1190	mean	abstract[74]|quantity[76]	giv[74]|new[76]	_	_
9-31	1191-1198	choline	abstract[74]|substance|quantity[76]	giv[74]|giv|new[76]	coref	11-6
9-32	1199-1212	concentration	abstract[74]|quantity[76]	giv[74]|new[76]	_	_
9-33	1213-1215	of	abstract[74]|quantity[76]	giv[74]|new[76]	_	_
9-34	1216-1219	9.6	abstract[74]|quantity[76]|quantity[77]	giv[74]|new[76]|new[77]	_	_
9-35	1220-1226	µmol/L	abstract[74]|quantity[76]|quantity[77]	giv[74]|new[76]|new[77]	_	_
9-36	1227-1233	before	abstract[74]|quantity[76]	giv[74]|new[76]	_	_
9-37	1234-1241	product	abstract[74]|quantity[76]|substance|event[79]	giv[74]|new[76]|new|giv[79]	coref|coref|coref|coref	14-11[140_79]|22-21|14-11[140_79]|22-21
9-38	1242-1248	intake	abstract[74]|quantity[76]|event[79]	giv[74]|new[76]|giv[79]	_	_
9-39	1249-1250	.	_	_	_	_

#Text=Moreover , baseline values were highly comparable within all groups and within the two kinetic days .
10-1	1251-1259	Moreover	_	_	_	_
10-2	1260-1261	,	_	_	_	_
10-3	1262-1270	baseline	abstract|abstract[81]	new|new[81]	coref|coref	28-24|28-24
10-4	1271-1277	values	abstract[81]	new[81]	_	_
10-5	1278-1282	were	_	_	_	_
10-6	1283-1289	highly	_	_	_	_
10-7	1290-1300	comparable	_	_	_	_
10-8	1301-1307	within	_	_	_	_
10-9	1308-1311	all	person[82]	new[82]	coref	18-9[180_82]
10-10	1312-1318	groups	person[82]	new[82]	_	_
10-11	1319-1322	and	_	_	_	_
10-12	1323-1329	within	_	_	_	_
10-13	1330-1333	the	time[83]	new[83]	_	_
10-14	1334-1337	two	time[83]	new[83]	_	_
10-15	1338-1345	kinetic	time[83]	new[83]	_	_
10-16	1346-1350	days	time[83]	new[83]	_	_
10-17	1351-1352	.	_	_	_	_

#Text=It is well known that choline levels are influenced by nutrition , and choline sources depend on the diet , In a normal Western diet , choline can be obtained from eggs , liver , soybeans and pork , where choline is present primarily as phosphatidylcholine .
11-1	1353-1355	It	abstract	giv	coref	13-2[113_0]
11-2	1356-1358	is	_	_	_	_
11-3	1359-1363	well	_	_	_	_
11-4	1364-1369	known	_	_	_	_
11-5	1370-1374	that	_	_	_	_
11-6	1375-1382	choline	substance|abstract[86]	giv|giv[86]	coref|coref|coref|coref	11-14|12-17[105_86]|11-14|12-17[105_86]
11-7	1383-1389	levels	abstract[86]	giv[86]	_	_
11-8	1390-1393	are	_	_	_	_
11-9	1394-1404	influenced	_	_	_	_
11-10	1405-1407	by	_	_	_	_
11-11	1408-1417	nutrition	substance	new	_	_
11-12	1418-1419	,	_	_	_	_
11-13	1420-1423	and	_	_	_	_
11-14	1424-1431	choline	substance|abstract[89]	giv|new[89]	coref|coref	11-27|11-27
11-15	1432-1439	sources	abstract[89]	new[89]	_	_
11-16	1440-1446	depend	_	_	_	_
11-17	1447-1449	on	_	_	_	_
11-18	1450-1453	the	abstract[90]	new[90]	_	_
11-19	1454-1458	diet	abstract[90]	new[90]	_	_
11-20	1459-1460	,	_	_	_	_
11-21	1461-1463	In	_	_	_	_
11-22	1464-1465	a	abstract[91]	new[91]	ana	12-1[0_91]
11-23	1466-1472	normal	abstract[91]	new[91]	_	_
11-24	1473-1480	Western	abstract[91]	new[91]	_	_
11-25	1481-1485	diet	abstract[91]	new[91]	_	_
11-26	1486-1487	,	_	_	_	_
11-27	1488-1495	choline	substance	giv	coref	11-41
11-28	1496-1499	can	_	_	_	_
11-29	1500-1502	be	_	_	_	_
11-30	1503-1511	obtained	_	_	_	_
11-31	1512-1516	from	_	_	_	_
11-32	1517-1521	eggs	substance	new	coref	13-10
11-33	1522-1523	,	_	_	_	_
11-34	1524-1529	liver	object	new	_	_
11-35	1530-1531	,	_	_	_	_
11-36	1532-1540	soybeans	plant	new	_	_
11-37	1541-1544	and	_	_	_	_
11-38	1545-1549	pork	plant	new	_	_
11-39	1550-1551	,	_	_	_	_
11-40	1552-1557	where	_	_	_	_
11-41	1558-1565	choline	substance	giv	coref	12-18
11-42	1566-1568	is	_	_	_	_
11-43	1569-1576	present	_	_	_	_
11-44	1577-1586	primarily	_	_	_	_
11-45	1587-1589	as	_	_	_	_
11-46	1590-1609	phosphatidylcholine	_	_	_	_
11-47	1610-1611	.	_	_	_	_

#Text=It was shown that the consumption of a small breakfast led to 25 – 30 % higher choline levels compared to the fasting condition , and that a high choline-containing diet resulted in an up to two-fold increase in plasma choline .
12-1	1612-1614	It	abstract	giv	coref	12-28[108_0]
12-2	1615-1618	was	_	_	_	_
12-3	1619-1624	shown	_	_	_	_
12-4	1625-1629	that	_	_	_	_
12-5	1630-1633	the	event[99]	new[99]	_	_
12-6	1634-1645	consumption	event[99]	new[99]	_	_
12-7	1646-1648	of	event[99]	new[99]	_	_
12-8	1649-1650	a	event[99]|event[100]	new[99]|new[100]	_	_
12-9	1651-1656	small	event[99]|event[100]	new[99]|new[100]	_	_
12-10	1657-1666	breakfast	event[99]|event[100]	new[99]|new[100]	_	_
12-11	1667-1670	led	_	_	_	_
12-12	1671-1673	to	_	_	_	_
12-13	1674-1676	25	quantity[101]	new[101]	_	_
12-14	1677-1678	–	quantity[101]	new[101]	_	_
12-15	1679-1681	30	quantity[101]|quantity	new[101]|new	_	_
12-16	1682-1683	%	quantity	new	_	_
12-17	1684-1690	higher	abstract[105]	giv[105]	coref	17-10[170_105]
12-18	1691-1698	choline	substance|abstract[105]	giv|giv[105]	coref	12-40[112_0]
12-19	1699-1705	levels	abstract[105]	giv[105]	_	_
12-20	1706-1714	compared	_	_	_	_
12-21	1715-1717	to	_	_	_	_
12-22	1718-1721	the	abstract[107]	new[107]	_	_
12-23	1722-1729	fasting	abstract|abstract[107]	new|new[107]	_	_
12-24	1730-1739	condition	abstract[107]	new[107]	_	_
12-25	1740-1741	,	_	_	_	_
12-26	1742-1745	and	_	_	_	_
12-27	1746-1750	that	_	_	_	_
12-28	1751-1752	a	abstract[108]	giv[108]	coref	15-16[150_108]
12-29	1753-1757	high	abstract[108]	giv[108]	_	_
12-30	1758-1776	choline-containing	abstract[108]	giv[108]	_	_
12-31	1777-1781	diet	abstract[108]	giv[108]	_	_
12-32	1782-1790	resulted	_	_	_	_
12-33	1791-1793	in	_	_	_	_
12-34	1794-1796	an	abstract[109]	new[109]	_	_
12-35	1797-1799	up	abstract[109]	new[109]	_	_
12-36	1800-1802	to	abstract[109]	new[109]	_	_
12-37	1803-1811	two-fold	abstract[109]|abstract[110]	new[109]|new[110]	coref	13-53[128_110]
12-38	1812-1820	increase	abstract[109]|abstract[110]	new[109]|new[110]	_	_
12-39	1821-1823	in	abstract[109]|abstract[110]	new[109]|new[110]	_	_
12-40	1824-1830	plasma	abstract[109]|abstract[110]|abstract|substance[112]	new[109]|new[110]|giv|giv[112]	coref|coref|coref|coref	13-15[0_112]|21-11|13-15[0_112]|21-11
12-41	1831-1838	choline	abstract[109]|abstract[110]|substance[112]	new[109]|new[110]|giv[112]	_	_
12-42	1839-1840	.	_	_	_	_

#Text=In a recent study by Cho et al. , eggs were provided as a choline source , which contained comparable amounts of choline ( 479 mg ) as the herein investigated study products ( choline bitartrate : 620 mg ; Superba Boost TM : 572 mg ) . Cho et al. reported a 1.6-fold increase in free choline after consumption of the egg meal , in comparison to the fruit control meal .
13-1	1841-1843	In	_	_	_	_
13-2	1844-1845	a	abstract[113]	giv[113]	coref	13-32[0_113]
13-3	1846-1852	recent	abstract[113]	giv[113]	_	_
13-4	1853-1858	study	abstract[113]	giv[113]	_	_
13-5	1859-1861	by	abstract[113]	giv[113]	_	_
13-6	1862-1865	Cho	abstract[113]|person	giv[113]|new	coref	13-49
13-7	1866-1868	et	abstract[113]	giv[113]	_	_
13-8	1869-1872	al.	abstract[113]	giv[113]	_	_
13-9	1873-1874	,	_	_	_	_
13-10	1875-1879	eggs	object	giv	_	_
13-11	1880-1884	were	_	_	_	_
13-12	1885-1893	provided	_	_	_	_
13-13	1894-1896	as	_	_	_	_
13-14	1897-1898	a	_	_	_	_
13-15	1899-1906	choline	substance	giv	coref	13-23
13-16	1907-1913	source	_	_	_	_
13-17	1914-1915	,	_	_	_	_
13-18	1916-1921	which	_	_	_	_
13-19	1922-1931	contained	_	_	_	_
13-20	1932-1942	comparable	quantity[117]	new[117]	_	_
13-21	1943-1950	amounts	quantity[117]	new[117]	_	_
13-22	1951-1953	of	quantity[117]	new[117]	_	_
13-23	1954-1961	choline	quantity[117]|substance	new[117]|giv	coref	13-35
13-24	1962-1963	(	quantity[117]	new[117]	_	_
13-25	1964-1967	479	quantity[117]|quantity[119]	new[117]|new[119]	_	_
13-26	1968-1970	mg	quantity[117]|quantity[119]	new[117]|new[119]	_	_
13-27	1971-1972	)	quantity[117]	new[117]	_	_
13-28	1973-1975	as	quantity[117]	new[117]	_	_
13-29	1976-1979	the	quantity[117]	new[117]	_	_
13-30	1980-1986	herein	quantity[117]	new[117]	_	_
13-31	1987-1999	investigated	quantity[117]	new[117]	_	_
13-32	2000-2005	study	quantity[117]|abstract	new[117]|giv	coref	14-7[138_0]
13-33	2006-2014	products	quantity[117]	new[117]	_	_
13-34	2015-2016	(	_	_	_	_
13-35	2017-2024	choline	substance|substance[122]	giv|giv[122]	coref|coref|coref|coref	13-57[129_0]|14-16[142_122]|13-57[129_0]|14-16[142_122]
13-36	2025-2035	bitartrate	substance[122]	giv[122]	_	_
13-37	2036-2037	:	substance[122]	giv[122]	_	_
13-38	2038-2041	620	substance[122]|quantity[123]	giv[122]|new[123]	_	_
13-39	2042-2044	mg	substance[122]|quantity[123]	giv[122]|new[123]	_	_
13-40	2045-2046	;	_	_	_	_
13-41	2047-2054	Superba	substance	giv	coref	14-21
13-42	2055-2060	Boost	_	_	_	_
13-43	2061-2063	TM	object	giv	coref	14-23[145_0]
13-44	2064-2065	:	_	_	_	_
13-45	2066-2069	572	quantity[126]	new[126]	_	_
13-46	2070-2072	mg	quantity[126]	new[126]	_	_
13-47	2073-2074	)	_	_	_	_
13-48	2075-2076	.	_	_	_	_
13-49	2077-2080	Cho	person	giv	_	_
13-50	2081-2083	et	_	_	_	_
13-51	2084-2087	al.	_	_	_	_
13-52	2088-2096	reported	_	_	_	_
13-53	2097-2098	a	abstract[128]	giv[128]	coref	14-3[137_128]
13-54	2099-2107	1.6-fold	abstract[128]	giv[128]	_	_
13-55	2108-2116	increase	abstract[128]	giv[128]	_	_
13-56	2117-2119	in	abstract[128]	giv[128]	_	_
13-57	2120-2124	free	abstract[128]|substance[129]	giv[128]|giv[129]	coref	14-4[0_129]
13-58	2125-2132	choline	abstract[128]|substance[129]	giv[128]|giv[129]	_	_
13-59	2133-2138	after	abstract[128]	giv[128]	_	_
13-60	2139-2150	consumption	abstract[128]|abstract[130]	giv[128]|new[130]	_	_
13-61	2151-2153	of	abstract[128]|abstract[130]	giv[128]|new[130]	_	_
13-62	2154-2157	the	abstract[128]|abstract[130]|object[132]	giv[128]|new[130]|new[132]	coref	13-69[135_132]
13-63	2158-2161	egg	abstract[128]|abstract[130]|object|object[132]	giv[128]|new[130]|new|new[132]	_	_
13-64	2162-2166	meal	abstract[128]|abstract[130]|object[132]	giv[128]|new[130]|new[132]	_	_
13-65	2167-2168	,	_	_	_	_
13-66	2169-2171	in	_	_	_	_
13-67	2172-2182	comparison	_	_	_	_
13-68	2183-2185	to	_	_	_	_
13-69	2186-2189	the	object[135]	giv[135]	_	_
13-70	2190-2195	fruit	plant|object[135]	new|giv[135]	_	_
13-71	2196-2203	control	event|object[135]	new|giv[135]	_	_
13-72	2204-2208	meal	object[135]	giv[135]	_	_
13-73	2209-2210	.	_	_	_	_

#Text=Correspondingly , the choline increase in the current study upon supplement intake was comparable ( choline bitartrate : 1.35-fold ; Superba Boost TM : 1.48-fold ) .
14-1	2211-2226	Correspondingly	_	_	_	_
14-2	2227-2228	,	_	_	_	_
14-3	2229-2232	the	abstract[137]	giv[137]	coref	17-6[168_137]
14-4	2233-2240	choline	substance|abstract[137]	giv|giv[137]	coref	14-16
14-5	2241-2249	increase	abstract[137]	giv[137]	_	_
14-6	2250-2252	in	abstract[137]	giv[137]	_	_
14-7	2253-2256	the	abstract[137]|abstract[138]	giv[137]|giv[138]	coref	15-11[149_138]
14-8	2257-2264	current	abstract[137]|abstract[138]	giv[137]|giv[138]	_	_
14-9	2265-2270	study	abstract[137]|abstract[138]	giv[137]|giv[138]	_	_
14-10	2271-2275	upon	abstract[137]|abstract[138]	giv[137]|giv[138]	_	_
14-11	2276-2286	supplement	abstract[137]|abstract[138]|substance|event[140]	giv[137]|giv[138]|new|giv[140]	coref|coref	16-19[161_140]|16-19[161_140]
14-12	2287-2293	intake	abstract[137]|abstract[138]|event[140]	giv[137]|giv[138]|giv[140]	_	_
14-13	2294-2297	was	_	_	_	_
14-14	2298-2308	comparable	_	_	_	_
14-15	2309-2310	(	_	_	_	_
14-16	2311-2318	choline	substance|substance[142]	giv|giv[142]	coref|coref|coref|coref	15-20|22-21[222_142]|15-20|22-21[222_142]
14-17	2319-2329	bitartrate	substance[142]	giv[142]	_	_
14-18	2330-2331	:	substance[142]	giv[142]	_	_
14-19	2332-2341	1.35-fold	substance[142]	giv[142]	_	_
14-20	2342-2343	;	_	_	_	_
14-21	2344-2351	Superba	substance|abstract[144]	giv|giv[144]	coref|coref	25-20|25-20
14-22	2352-2357	Boost	abstract[144]	giv[144]	_	_
14-23	2358-2360	TM	abstract[144]|object[145]	giv[144]|giv[145]	coref	25-20[248_145]
14-24	2361-2362	:	abstract[144]|object[145]	giv[144]|giv[145]	_	_
14-25	2363-2372	1.48-fold	abstract[144]|object[145]	giv[144]|giv[145]	_	_
14-26	2373-2374	)	_	_	_	_
14-27	2375-2376	.	_	_	_	_

#Text=To control for confounding factors of food , subjects of the present study adhered to a diet low in choline three days before the study intervention and consumed standardized meals during the kinetic days .
15-1	2377-2379	To	_	_	_	_
15-2	2380-2387	control	_	_	_	_
15-3	2388-2391	for	_	_	_	_
15-4	2392-2403	confounding	_	_	_	_
15-5	2404-2411	factors	abstract[146]	new[146]	_	_
15-6	2412-2414	of	abstract[146]	new[146]	_	_
15-7	2415-2419	food	abstract[146]|substance	new[146]|new	_	_
15-8	2420-2421	,	_	_	_	_
15-9	2422-2430	subjects	abstract[148]	new[148]	coref	16-11[159_148]
15-10	2431-2433	of	abstract[148]	new[148]	_	_
15-11	2434-2437	the	abstract[148]|abstract[149]	new[148]|giv[149]	coref	15-25[0_149]
15-12	2438-2445	present	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
15-13	2446-2451	study	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
15-14	2452-2459	adhered	_	_	_	_
15-15	2460-2462	to	_	_	_	_
15-16	2463-2464	a	abstract[150]	giv[150]	_	_
15-17	2465-2469	diet	abstract[150]	giv[150]	_	_
15-18	2470-2473	low	_	_	_	_
15-19	2474-2476	in	_	_	_	_
15-20	2477-2484	choline	substance	giv	coref	16-32
15-21	2485-2490	three	time[152]	new[152]	_	_
15-22	2491-2495	days	time[152]	new[152]	_	_
15-23	2496-2502	before	_	_	_	_
15-24	2503-2506	the	event[154]	new[154]	_	_
15-25	2507-2512	study	abstract|event[154]	giv|new[154]	coref	16-6
15-26	2513-2525	intervention	event[154]	new[154]	_	_
15-27	2526-2529	and	_	_	_	_
15-28	2530-2538	consumed	_	_	_	_
15-29	2539-2551	standardized	object[155]	new[155]	_	_
15-30	2552-2557	meals	object[155]	new[155]	_	_
15-31	2558-2564	during	_	_	_	_
15-32	2565-2568	the	time[156]	new[156]	_	_
15-33	2569-2576	kinetic	time[156]	new[156]	_	_
15-34	2577-2581	days	time[156]	new[156]	_	_
15-35	2582-2583	.	_	_	_	_

#Text=In addition , a parallel study arm was included , whose subjects underwent a single kinetic dose after the intake of fish oil as a placebo control that was devoid of choline .
16-1	2584-2586	In	_	_	_	_
16-2	2587-2595	addition	_	_	_	_
16-3	2596-2597	,	_	_	_	_
16-4	2598-2599	a	abstract[158]	new[158]	_	_
16-5	2600-2608	parallel	abstract[158]	new[158]	_	_
16-6	2609-2614	study	abstract|abstract[158]	giv|new[158]	coref	18-10
16-7	2615-2618	arm	abstract[158]	new[158]	_	_
16-8	2619-2622	was	_	_	_	_
16-9	2623-2631	included	_	_	_	_
16-10	2632-2633	,	_	_	_	_
16-11	2634-2639	whose	abstract[159]	giv[159]	_	_
16-12	2640-2648	subjects	abstract[159]	giv[159]	_	_
16-13	2649-2658	underwent	_	_	_	_
16-14	2659-2660	a	abstract[160]	new[160]	_	_
16-15	2661-2667	single	abstract[160]	new[160]	_	_
16-16	2668-2675	kinetic	abstract[160]	new[160]	_	_
16-17	2676-2680	dose	abstract[160]	new[160]	_	_
16-18	2681-2686	after	_	_	_	_
16-19	2687-2690	the	event[161]	giv[161]	coref	25-24[0_161]
16-20	2691-2697	intake	event[161]	giv[161]	_	_
16-21	2698-2700	of	event[161]	giv[161]	_	_
16-22	2701-2705	fish	event[161]|animal|substance[163]	giv[161]|new|giv[163]	coref|coref	20-1[199_163]|20-1[199_163]
16-23	2706-2709	oil	event[161]|substance[163]	giv[161]|giv[163]	_	_
16-24	2710-2712	as	event[161]|substance[163]	giv[161]|giv[163]	_	_
16-25	2713-2714	a	event[161]|substance[163]	giv[161]|giv[163]	_	_
16-26	2715-2722	placebo	event[161]|substance[163]|person	giv[161]|giv[163]|new	_	_
16-27	2723-2730	control	event[161]|substance[163]	giv[161]|giv[163]	_	_
16-28	2731-2735	that	_	_	_	_
16-29	2736-2739	was	_	_	_	_
16-30	2740-2746	devoid	_	_	_	_
16-31	2747-2749	of	_	_	_	_
16-32	2750-2757	choline	substance	giv	coref	17-10
16-33	2758-2759	.	_	_	_	_

#Text=Of note , we observed a minor increase in choline levels in the placebo group after the 4 h time point ; thus , the standardized lunch served after four hours could have contributed to this elevation .
17-1	2760-2762	Of	_	_	_	_
17-2	2763-2767	note	abstract	new	_	_
17-3	2768-2769	,	_	_	_	_
17-4	2770-2772	we	person	acc	ana	19-10
17-5	2773-2781	observed	_	_	_	_
17-6	2782-2783	a	abstract[168]	giv[168]	coref	22-7[216_168]
17-7	2784-2789	minor	abstract[168]	giv[168]	_	_
17-8	2790-2798	increase	abstract[168]	giv[168]	_	_
17-9	2799-2801	in	abstract[168]	giv[168]	_	_
17-10	2802-2809	choline	abstract[168]|substance|abstract[170]	giv[168]|giv|giv[170]	coref|coref|coref|coref	18-13|19-20[188_170]|18-13|19-20[188_170]
17-11	2810-2816	levels	abstract[168]|abstract[170]	giv[168]|giv[170]	_	_
17-12	2817-2819	in	abstract[168]|abstract[170]	giv[168]|giv[170]	_	_
17-13	2820-2823	the	abstract[168]|abstract[170]|person[171]	giv[168]|giv[170]|new[171]	_	_
17-14	2824-2831	placebo	abstract[168]|abstract[170]|person[171]	giv[168]|giv[170]|new[171]	_	_
17-15	2832-2837	group	abstract[168]|abstract[170]|person[171]	giv[168]|giv[170]|new[171]	_	_
17-16	2838-2843	after	abstract[168]|abstract[170]|person[171]	giv[168]|giv[170]|new[171]	_	_
17-17	2844-2847	the	abstract[168]|abstract[170]|person[171]|time[174]	giv[168]|giv[170]|new[171]|new[174]	_	_
17-18	2848-2849	4	abstract[168]|abstract[170]|person[171]|time[174]	giv[168]|giv[170]|new[171]|new[174]	_	_
17-19	2850-2851	h	abstract[168]|abstract[170]|person[171]|quantity|time[174]	giv[168]|giv[170]|new[171]|new|new[174]	_	_
17-20	2852-2856	time	abstract[168]|abstract[170]|person[171]|event|time[174]	giv[168]|giv[170]|new[171]|new|new[174]	_	_
17-21	2857-2862	point	abstract[168]|abstract[170]|person[171]|time[174]	giv[168]|giv[170]|new[171]|new[174]	_	_
17-22	2863-2864	;	_	_	_	_
17-23	2865-2869	thus	_	_	_	_
17-24	2870-2871	,	_	_	_	_
17-25	2872-2875	the	event[175]	new[175]	_	_
17-26	2876-2888	standardized	event[175]	new[175]	_	_
17-27	2889-2894	lunch	event[175]	new[175]	_	_
17-28	2895-2901	served	_	_	_	_
17-29	2902-2907	after	_	_	_	_
17-30	2908-2912	four	time[176]	new[176]	_	_
17-31	2913-2918	hours	time[176]	new[176]	_	_
17-32	2919-2924	could	_	_	_	_
17-33	2925-2929	have	_	_	_	_
17-34	2930-2941	contributed	_	_	_	_
17-35	2942-2944	to	_	_	_	_
17-36	2945-2949	this	abstract[177]	new[177]	coref	19-32[191_177]
17-37	2950-2959	elevation	abstract[177]	new[177]	_	_
17-38	2960-2961	.	_	_	_	_

#Text=However , no such effect was seen in the study groups receiving choline supplements .
18-1	2962-2969	However	_	_	_	_
18-2	2970-2971	,	_	_	_	_
18-3	2972-2974	no	abstract[178]	new[178]	_	_
18-4	2975-2979	such	abstract[178]	new[178]	_	_
18-5	2980-2986	effect	abstract[178]	new[178]	_	_
18-6	2987-2990	was	_	_	_	_
18-7	2991-2995	seen	_	_	_	_
18-8	2996-2998	in	_	_	_	_
18-9	2999-3002	the	person[180]	giv[180]	_	_
18-10	3003-3008	study	abstract|person[180]	giv|giv[180]	coref	21-2[206_0]
18-11	3009-3015	groups	person[180]	giv[180]	_	_
18-12	3016-3025	receiving	_	_	_	_
18-13	3026-3033	choline	substance|substance[182]	giv|new[182]	coref|coref	19-20|19-20
18-14	3034-3045	supplements	substance[182]	new[182]	_	_
18-15	3046-3047	.	_	_	_	_

#Text=In addition , by implementing the control group , we were able to exclude possible circadian rhythm-dependent variations in choline levels , in contrast to Park et al. , who observed a slight elevation of free choline levels in the afternoon during a 12 h-lasting observation of endogenous choline levels .
19-1	3048-3050	In	_	_	_	_
19-2	3051-3059	addition	_	_	_	_
19-3	3060-3061	,	_	_	_	_
19-4	3062-3064	by	_	_	_	_
19-5	3065-3077	implementing	_	_	_	_
19-6	3078-3081	the	person[183]	new[183]	_	_
19-7	3082-3089	control	person[183]	new[183]	_	_
19-8	3090-3095	group	person[183]	new[183]	_	_
19-9	3096-3097	,	_	_	_	_
19-10	3098-3100	we	person	giv	ana	22-5
19-11	3101-3105	were	_	_	_	_
19-12	3106-3110	able	_	_	_	_
19-13	3111-3113	to	_	_	_	_
19-14	3114-3121	exclude	_	_	_	_
19-15	3122-3130	possible	person[185]	new[185]	_	_
19-16	3131-3140	circadian	person[185]	new[185]	_	_
19-17	3141-3157	rhythm-dependent	abstract[186]	new[186]	_	_
19-18	3158-3168	variations	abstract[186]	new[186]	_	_
19-19	3169-3171	in	abstract[186]	new[186]	_	_
19-20	3172-3179	choline	abstract[186]|substance|abstract[188]	new[186]|giv|giv[188]	coref|coref|coref|coref	19-37|19-36[193_188]|19-37|19-36[193_188]
19-21	3180-3186	levels	abstract[186]|abstract[188]	new[186]|giv[188]	_	_
19-22	3187-3188	,	_	_	_	_
19-23	3189-3191	in	_	_	_	_
19-24	3192-3200	contrast	abstract[189]	new[189]	_	_
19-25	3201-3203	to	abstract[189]	new[189]	_	_
19-26	3204-3208	Park	abstract[189]|person	new[189]|new	_	_
19-27	3209-3211	et	abstract[189]	new[189]	_	_
19-28	3212-3215	al.	abstract[189]	new[189]	_	_
19-29	3216-3217	,	_	_	_	_
19-30	3218-3221	who	_	_	_	_
19-31	3222-3230	observed	_	_	_	_
19-32	3231-3232	a	abstract[191]	giv[191]	_	_
19-33	3233-3239	slight	abstract[191]	giv[191]	_	_
19-34	3240-3249	elevation	abstract[191]	giv[191]	_	_
19-35	3250-3252	of	abstract[191]	giv[191]	_	_
19-36	3253-3257	free	abstract[191]|abstract[193]	giv[191]|giv[193]	coref	19-48[197_193]
19-37	3258-3265	choline	abstract[191]|substance|abstract[193]	giv[191]|giv|giv[193]	coref	19-49
19-38	3266-3272	levels	abstract[191]|abstract[193]	giv[191]|giv[193]	_	_
19-39	3273-3275	in	abstract[191]|abstract[193]	giv[191]|giv[193]	_	_
19-40	3276-3279	the	abstract[191]|abstract[193]|time[194]	giv[191]|giv[193]|new[194]	_	_
19-41	3280-3289	afternoon	abstract[191]|abstract[193]|time[194]	giv[191]|giv[193]|new[194]	_	_
19-42	3290-3296	during	_	_	_	_
19-43	3297-3298	a	event[195]	new[195]	_	_
19-44	3299-3301	12	event[195]	new[195]	_	_
19-45	3302-3311	h-lasting	event[195]	new[195]	_	_
19-46	3312-3323	observation	event[195]	new[195]	_	_
19-47	3324-3326	of	event[195]	new[195]	_	_
19-48	3327-3337	endogenous	event[195]|abstract[197]	new[195]|giv[197]	coref	21-11[210_197]
19-49	3338-3345	choline	event[195]|substance|abstract[197]	new[195]|giv|giv[197]	coref	21-12
19-50	3346-3352	levels	event[195]|abstract[197]	new[195]|giv[197]	_	_
19-51	3353-3354	.	_	_	_	_

#Text=Krill oil is increasingly recognized as a useful source of phosphatidylcholine , in addition to its acknowledged role in providing the omega-3 fatty acids EPA and DHA .
20-1	3355-3360	Krill	abstract|substance[199]	giv|giv[199]	_	_
20-2	3361-3364	oil	substance[199]	giv[199]	_	_
20-3	3365-3367	is	_	_	_	_
20-4	3368-3380	increasingly	_	_	_	_
20-5	3381-3391	recognized	_	_	_	_
20-6	3392-3394	as	_	_	_	_
20-7	3395-3396	a	_	_	_	_
20-8	3397-3403	useful	_	_	_	_
20-9	3404-3410	source	_	_	_	_
20-10	3411-3413	of	_	_	_	_
20-11	3414-3433	phosphatidylcholine	substance	new	ana	20-16
20-12	3434-3435	,	_	_	_	_
20-13	3436-3438	in	_	_	_	_
20-14	3439-3447	addition	_	_	_	_
20-15	3448-3450	to	_	_	_	_
20-16	3451-3454	its	substance|abstract[202]	giv|new[202]	coref|coref	21-6|21-6
20-17	3455-3467	acknowledged	abstract[202]	new[202]	_	_
20-18	3468-3472	role	abstract[202]	new[202]	_	_
20-19	3473-3475	in	_	_	_	_
20-20	3476-3485	providing	_	_	_	_
20-21	3486-3489	the	abstract[203]	new[203]	_	_
20-22	3490-3497	omega-3	abstract[203]	new[203]	_	_
20-23	3498-3503	fatty	abstract[203]	new[203]	_	_
20-24	3504-3509	acids	abstract[203]	new[203]	_	_
20-25	3510-3513	EPA	abstract[203]|organization	new[203]|new	_	_
20-26	3514-3517	and	abstract[203]	new[203]	_	_
20-27	3518-3521	DHA	abstract[203]|abstract	new[203]|new	_	_
20-28	3522-3523	.	_	_	_	_

#Text=In a former study , phosphatidylcholine was shown to raise plasma choline levels more efficiently compared to ingestion of free choline as choline chloride .
21-1	3524-3526	In	_	_	_	_
21-2	3527-3528	a	abstract[206]	giv[206]	coref	22-2[214_206]
21-3	3529-3535	former	abstract[206]	giv[206]	_	_
21-4	3536-3541	study	abstract[206]	giv[206]	_	_
21-5	3542-3543	,	_	_	_	_
21-6	3544-3563	phosphatidylcholine	substance	giv	coref	22-16[219_0]
21-7	3564-3567	was	_	_	_	_
21-8	3568-3573	shown	_	_	_	_
21-9	3574-3576	to	_	_	_	_
21-10	3577-3582	raise	_	_	_	_
21-11	3583-3589	plasma	abstract|abstract[210]	giv|giv[210]	coref|coref	28-11[283_210]|28-11[283_210]
21-12	3590-3597	choline	substance|abstract[210]	giv|giv[210]	coref	21-20[212_0]
21-13	3598-3604	levels	abstract[210]	giv[210]	_	_
21-14	3605-3609	more	_	_	_	_
21-15	3610-3621	efficiently	_	_	_	_
21-16	3622-3630	compared	_	_	_	_
21-17	3631-3633	to	_	_	_	_
21-18	3634-3643	ingestion	event[211]	new[211]	_	_
21-19	3644-3646	of	event[211]	new[211]	_	_
21-20	3647-3651	free	event[211]|substance[212]	new[211]|giv[212]	coref	21-23[0_212]
21-21	3652-3659	choline	event[211]|substance[212]	new[211]|giv[212]	_	_
21-22	3660-3662	as	event[211]	new[211]	_	_
21-23	3663-3670	choline	event[211]|substance	new[211]|giv	coref	22-11
21-24	3671-3679	chloride	event[211]	new[211]	_	_
21-25	3680-3681	.	_	_	_	_

#Text=In the current study we observed a significant increase of choline after single doses of both phosphatidylcholine and the reference product choline bitartrate ; however , phosphatidylcholine was not more efficient , since there were no significant differences in the pharmacokinetic endpoints AUC and Cmax .
22-1	3682-3684	In	_	_	_	_
22-2	3685-3688	the	abstract[214]	giv[214]	coref	23-5[229_214]
22-3	3689-3696	current	abstract[214]	giv[214]	_	_
22-4	3697-3702	study	abstract[214]	giv[214]	_	_
22-5	3703-3705	we	person	giv	ana	24-7
22-6	3706-3714	observed	_	_	_	_
22-7	3715-3716	a	abstract[216]	giv[216]	coref	25-14[245_216]
22-8	3717-3728	significant	abstract[216]	giv[216]	_	_
22-9	3729-3737	increase	abstract[216]	giv[216]	_	_
22-10	3738-3740	of	abstract[216]	giv[216]	_	_
22-11	3741-3748	choline	abstract[216]|substance	giv[216]|giv	coref	22-22
22-12	3749-3754	after	abstract[216]	giv[216]	_	_
22-13	3755-3761	single	abstract[216]|abstract[218]	giv[216]|new[218]	_	_
22-14	3762-3767	doses	abstract[216]|abstract[218]	giv[216]|new[218]	_	_
22-15	3768-3770	of	abstract[216]|abstract[218]	giv[216]|new[218]	_	_
22-16	3771-3775	both	abstract[216]|abstract[218]|substance[219]	giv[216]|new[218]|giv[219]	coref	22-27[0_219]
22-17	3776-3795	phosphatidylcholine	abstract[216]|abstract[218]|substance[219]	giv[216]|new[218]|giv[219]	_	_
22-18	3796-3799	and	abstract[216]|abstract[218]	giv[216]|new[218]	_	_
22-19	3800-3803	the	abstract[216]|abstract[218]	giv[216]|new[218]	_	_
22-20	3804-3813	reference	abstract[216]|abstract[218]	giv[216]|new[218]	_	_
22-21	3814-3821	product	abstract[216]|abstract[218]|substance|substance[222]	giv[216]|new[218]|giv|giv[222]	coref|coref	24-10[236_222]|24-10[236_222]
22-22	3822-3829	choline	abstract[216]|abstract[218]|substance|substance[222]	giv[216]|new[218]|giv|giv[222]	coref	23-20
22-23	3830-3840	bitartrate	abstract[216]|abstract[218]|substance[222]	giv[216]|new[218]|giv[222]	_	_
22-24	3841-3842	;	_	_	_	_
22-25	3843-3850	however	_	_	_	_
22-26	3851-3852	,	_	_	_	_
22-27	3853-3872	phosphatidylcholine	substance	giv	coref	25-18
22-28	3873-3876	was	_	_	_	_
22-29	3877-3880	not	_	_	_	_
22-30	3881-3885	more	_	_	_	_
22-31	3886-3895	efficient	_	_	_	_
22-32	3896-3897	,	_	_	_	_
22-33	3898-3903	since	_	_	_	_
22-34	3904-3909	there	_	_	_	_
22-35	3910-3914	were	_	_	_	_
22-36	3915-3917	no	abstract[224]	new[224]	coref	23-12[230_224]
22-37	3918-3929	significant	abstract[224]	new[224]	_	_
22-38	3930-3941	differences	abstract[224]	new[224]	_	_
22-39	3942-3944	in	abstract[224]	new[224]	_	_
22-40	3945-3948	the	abstract[224]|abstract[226]	new[224]|new[226]	_	_
22-41	3949-3964	pharmacokinetic	abstract[224]|abstract|abstract[226]	new[224]|giv|new[226]	_	_
22-42	3965-3974	endpoints	abstract[224]|abstract[226]	new[224]|new[226]	_	_
22-43	3975-3978	AUC	_	_	_	_
22-44	3979-3982	and	_	_	_	_
22-45	3983-3987	Cmax	abstract	new	_	_
22-46	3988-3989	.	_	_	_	_

#Text=This discrepancy compared to the former study could be due to possible differences in the bioavailability of the chosen choline salts .
23-1	3990-3994	This	abstract[228]	new[228]	_	_
23-2	3995-4006	discrepancy	abstract[228]	new[228]	_	_
23-3	4007-4015	compared	_	_	_	_
23-4	4016-4018	to	_	_	_	_
23-5	4019-4022	the	abstract[229]	giv[229]	coref	25-10[244_229]
23-6	4023-4029	former	abstract[229]	giv[229]	_	_
23-7	4030-4035	study	abstract[229]	giv[229]	_	_
23-8	4036-4041	could	_	_	_	_
23-9	4042-4044	be	_	_	_	_
23-10	4045-4048	due	_	_	_	_
23-11	4049-4051	to	_	_	_	_
23-12	4052-4060	possible	abstract[230]	giv[230]	coref	26-12[256_230]
23-13	4061-4072	differences	abstract[230]	giv[230]	_	_
23-14	4073-4075	in	abstract[230]	giv[230]	_	_
23-15	4076-4079	the	abstract[230]|substance[231]	giv[230]|new[231]	coref	24-13[239_231]
23-16	4080-4095	bioavailability	abstract[230]|substance[231]	giv[230]|new[231]	_	_
23-17	4096-4098	of	abstract[230]|substance[231]	giv[230]|new[231]	_	_
23-18	4099-4102	the	abstract[230]|substance[231]|substance[233]	giv[230]|new[231]|new[233]	_	_
23-19	4103-4109	chosen	abstract[230]|substance[231]|substance[233]	giv[230]|new[231]|new[233]	_	_
23-20	4110-4117	choline	abstract[230]|substance[231]|substance|substance[233]	giv[230]|new[231]|giv|new[233]	coref	24-13
23-21	4118-4123	salts	abstract[230]|substance[231]|substance[233]	giv[230]|new[231]|new[233]	_	_
23-22	4124-4125	.	_	_	_	_

#Text=However , to the best of our knowledge , choline bitartrate and choline chloride bioavailability has not been directly compared to date .
24-1	4126-4133	However	_	_	_	_
24-2	4134-4135	,	_	_	_	_
24-3	4136-4138	to	_	_	_	_
24-4	4139-4142	the	_	_	_	_
24-5	4143-4147	best	_	_	_	_
24-6	4148-4150	of	_	_	_	_
24-7	4151-4154	our	person|abstract[235]	giv|new[235]	ana|ana	28-1|28-1
24-8	4155-4164	knowledge	abstract[235]	new[235]	_	_
24-9	4165-4166	,	_	_	_	_
24-10	4167-4174	choline	substance[236]	giv[236]	coref	25-27[251_236]
24-11	4175-4185	bitartrate	substance[236]	giv[236]	_	_
24-12	4186-4189	and	_	_	_	_
24-13	4190-4197	choline	substance|substance[239]	giv|giv[239]	coref|coref	25-7[243_0]|25-7[243_0]
24-14	4198-4206	chloride	abstract|substance[239]	new|giv[239]	coref	28-14[285_0]
24-15	4207-4222	bioavailability	substance[239]	giv[239]	_	_
24-16	4223-4226	has	_	_	_	_
24-17	4227-4230	not	_	_	_	_
24-18	4231-4235	been	_	_	_	_
24-19	4236-4244	directly	_	_	_	_
24-20	4245-4253	compared	_	_	_	_
24-21	4254-4256	to	_	_	_	_
24-22	4257-4261	date	time	new	_	_
24-23	4262-4263	.	_	_	_	_

#Text=Still , the uptake profile of free choline in the current study indicated a slower increase upon phosphatidylcholine ( Superba Boost TM ) intake compared to choline bitartrate .
25-1	4264-4269	Still	_	_	_	_
25-2	4270-4271	,	_	_	_	_
25-3	4272-4275	the	abstract[242]	new[242]	_	_
25-4	4276-4282	uptake	abstract|abstract[242]	giv|new[242]	_	_
25-5	4283-4290	profile	abstract[242]	new[242]	_	_
25-6	4291-4293	of	abstract[242]	new[242]	_	_
25-7	4294-4298	free	abstract[242]|substance[243]	new[242]|giv[243]	coref	25-27[0_243]
25-8	4299-4306	choline	abstract[242]|substance[243]	new[242]|giv[243]	_	_
25-9	4307-4309	in	abstract[242]|substance[243]	new[242]|giv[243]	_	_
25-10	4310-4313	the	abstract[242]|substance[243]|abstract[244]	new[242]|giv[243]|giv[244]	coref	26-7[0_244]
25-11	4314-4321	current	abstract[242]|substance[243]|abstract[244]	new[242]|giv[243]|giv[244]	_	_
25-12	4322-4327	study	abstract[242]|substance[243]|abstract[244]	new[242]|giv[243]|giv[244]	_	_
25-13	4328-4337	indicated	_	_	_	_
25-14	4338-4339	a	abstract[245]	giv[245]	_	_
25-15	4340-4346	slower	abstract[245]	giv[245]	_	_
25-16	4347-4355	increase	abstract[245]	giv[245]	_	_
25-17	4356-4360	upon	abstract[245]	giv[245]	_	_
25-18	4361-4380	phosphatidylcholine	abstract[245]|substance	giv[245]|giv	coref	27-1[262_0]
25-19	4381-4382	(	_	_	_	_
25-20	4383-4390	Superba	substance|abstract[248]	giv|giv[248]	_	_
25-21	4391-4396	Boost	abstract[248]	giv[248]	_	_
25-22	4397-4399	TM	abstract[248]	giv[248]	_	_
25-23	4400-4401	)	_	_	_	_
25-24	4402-4408	intake	event	giv	coref	28-25[289_0]
25-25	4409-4417	compared	_	_	_	_
25-26	4418-4420	to	_	_	_	_
25-27	4421-4428	choline	substance|substance[251]	giv|giv[251]	coref|coref|coref|coref	26-17|27-41[274_251]|26-17|27-41[274_251]
25-28	4429-4439	bitartrate	substance[251]	giv[251]	_	_
25-29	4440-4441	.	_	_	_	_

#Text=This difference in Tmax between the study products could result from the structural differences between the choline forms and from the associated differences in absorption and metabolism .
26-1	4442-4446	This	abstract[252]	new[252]	_	_
26-2	4447-4457	difference	abstract[252]	new[252]	_	_
26-3	4458-4460	in	abstract[252]	new[252]	_	_
26-4	4461-4465	Tmax	abstract[252]|abstract[253]	new[252]|new[253]	_	_
26-5	4466-4473	between	abstract[252]|abstract[253]	new[252]|new[253]	_	_
26-6	4474-4477	the	abstract[252]|abstract[253]|object[255]	new[252]|new[253]|new[255]	_	_
26-7	4478-4483	study	abstract[252]|abstract[253]|abstract|object[255]	new[252]|new[253]|giv|new[255]	_	_
26-8	4484-4492	products	abstract[252]|abstract[253]|object[255]	new[252]|new[253]|new[255]	_	_
26-9	4493-4498	could	_	_	_	_
26-10	4499-4505	result	_	_	_	_
26-11	4506-4510	from	_	_	_	_
26-12	4511-4514	the	abstract[256]	giv[256]	coref	26-21[259_256]
26-13	4515-4525	structural	abstract[256]	giv[256]	_	_
26-14	4526-4537	differences	abstract[256]	giv[256]	_	_
26-15	4538-4545	between	abstract[256]	giv[256]	_	_
26-16	4546-4549	the	abstract[256]|substance[258]	giv[256]|new[258]	_	_
26-17	4550-4557	choline	abstract[256]|substance|substance[258]	giv[256]|giv|new[258]	coref	27-18[266_0]
26-18	4558-4563	forms	abstract[256]|substance[258]	giv[256]|new[258]	_	_
26-19	4564-4567	and	_	_	_	_
26-20	4568-4572	from	_	_	_	_
26-21	4573-4576	the	abstract[259]	giv[259]	_	_
26-22	4577-4587	associated	abstract[259]	giv[259]	_	_
26-23	4588-4599	differences	abstract[259]	giv[259]	_	_
26-24	4600-4602	in	abstract[259]	giv[259]	_	_
26-25	4603-4613	absorption	abstract[259]|abstract	giv[259]|new	_	_
26-26	4614-4617	and	abstract[259]	giv[259]	_	_
26-27	4618-4628	metabolism	abstract[259]|abstract	giv[259]|new	_	_
26-28	4629-4630	.	_	_	_	_

#Text=Phosphatidylcholine and/or its isoforms may be absorbed intact and can also be hydrolyzed into phosphatidic acid and free choline by phospholipase D. Due to this conversion step , it supposedly takes longer to obtain free choline from phosphatidylcholine compared to choline bitartrate , where free choline from the salt structure is more rapidly available .
27-1	4631-4650	Phosphatidylcholine	substance[262]	giv[262]	ana	27-29[0_262]
27-2	4651-4657	and/or	substance[262]	giv[262]	_	_
27-3	4658-4661	its	substance[262]|substance[263]	giv[262]|new[263]	_	_
27-4	4662-4670	isoforms	substance[262]|substance[263]	giv[262]|new[263]	_	_
27-5	4671-4674	may	_	_	_	_
27-6	4675-4677	be	_	_	_	_
27-7	4678-4686	absorbed	_	_	_	_
27-8	4687-4693	intact	_	_	_	_
27-9	4694-4697	and	_	_	_	_
27-10	4698-4701	can	_	_	_	_
27-11	4702-4706	also	_	_	_	_
27-12	4707-4709	be	_	_	_	_
27-13	4710-4720	hydrolyzed	_	_	_	_
27-14	4721-4725	into	_	_	_	_
27-15	4726-4738	phosphatidic	person|substance[265]	new|new[265]	_	_
27-16	4739-4743	acid	substance[265]	new[265]	_	_
27-17	4744-4747	and	_	_	_	_
27-18	4748-4752	free	substance[266]	giv[266]	coref	27-35[271_266]
27-19	4753-4760	choline	substance[266]	giv[266]	_	_
27-20	4761-4763	by	_	_	_	_
27-21	4764-4777	phospholipase	abstract[267]	new[267]	_	_
27-22	4778-4780	D.	abstract[267]	new[267]	_	_
27-23	4781-4784	Due	abstract[267]	new[267]	_	_
27-24	4785-4787	to	_	_	_	_
27-25	4788-4792	this	event[269]	new[269]	_	_
27-26	4793-4803	conversion	abstract|event[269]	new|new[269]	_	_
27-27	4804-4808	step	event[269]	new[269]	_	_
27-28	4809-4810	,	_	_	_	_
27-29	4811-4813	it	substance	giv	coref	27-38
27-30	4814-4824	supposedly	_	_	_	_
27-31	4825-4830	takes	_	_	_	_
27-32	4831-4837	longer	_	_	_	_
27-33	4838-4840	to	_	_	_	_
27-34	4841-4847	obtain	_	_	_	_
27-35	4848-4852	free	substance[271]	giv[271]	coref	27-41[0_271]
27-36	4853-4860	choline	substance[271]	giv[271]	_	_
27-37	4861-4865	from	_	_	_	_
27-38	4866-4885	phosphatidylcholine	substance	giv	coref	28-28
27-39	4886-4894	compared	_	_	_	_
27-40	4895-4897	to	_	_	_	_
27-41	4898-4905	choline	substance|substance[274]	giv|giv[274]	coref|coref	27-45[275_0]|27-45[275_0]
27-42	4906-4916	bitartrate	substance[274]	giv[274]	_	_
27-43	4917-4918	,	_	_	_	_
27-44	4919-4924	where	_	_	_	_
27-45	4925-4929	free	substance[275]	giv[275]	coref	28-11[0_275]
27-46	4930-4937	choline	substance[275]	giv[275]	_	_
27-47	4938-4942	from	substance[275]	giv[275]	_	_
27-48	4943-4946	the	substance[275]|abstract[277]	giv[275]|new[277]	_	_
27-49	4947-4951	salt	substance[275]|substance|abstract[277]	giv[275]|new|new[277]	_	_
27-50	4952-4961	structure	substance[275]|abstract[277]	giv[275]|new[277]	_	_
27-51	4962-4964	is	_	_	_	_
27-52	4965-4969	more	_	_	_	_
27-53	4970-4977	rapidly	_	_	_	_
27-54	4978-4987	available	_	_	_	_
27-55	4988-4989	.	_	_	_	_

#Text=Our findings are in agreement with former findings showing that choline levels after choline chloride reached peak levels earlier and were reduced to baseline earlier than after phosphatidylcholine intake , where levels remained elevated for 12 h.
28-1	4990-4993	Our	person|abstract[279]	giv|new[279]	_	_
28-2	4994-5002	findings	abstract[279]	new[279]	_	_
28-3	5003-5006	are	_	_	_	_
28-4	5007-5009	in	_	_	_	_
28-5	5010-5019	agreement	abstract[280]	new[280]	_	_
28-6	5020-5024	with	abstract[280]	new[280]	_	_
28-7	5025-5031	former	abstract[280]|abstract[281]	new[280]|new[281]	_	_
28-8	5032-5040	findings	abstract[280]|abstract[281]	new[280]|new[281]	_	_
28-9	5041-5048	showing	_	_	_	_
28-10	5049-5053	that	_	_	_	_
28-11	5054-5061	choline	substance|abstract[283]	giv|giv[283]	coref|coref|coref|coref	28-14|28-17[286_283]|28-14|28-17[286_283]
28-12	5062-5068	levels	abstract[283]	giv[283]	_	_
28-13	5069-5074	after	_	_	_	_
28-14	5075-5082	choline	substance|abstract[285]	giv|giv[285]	_	_
28-15	5083-5091	chloride	abstract[285]	giv[285]	_	_
28-16	5092-5099	reached	_	_	_	_
28-17	5100-5104	peak	abstract[286]	giv[286]	coref	28-32[0_286]
28-18	5105-5111	levels	abstract[286]	giv[286]	_	_
28-19	5112-5119	earlier	_	_	_	_
28-20	5120-5123	and	_	_	_	_
28-21	5124-5128	were	_	_	_	_
28-22	5129-5136	reduced	_	_	_	_
28-23	5137-5139	to	_	_	_	_
28-24	5140-5148	baseline	abstract	giv	_	_
28-25	5149-5156	earlier	event[289]	giv[289]	_	_
28-26	5157-5161	than	event[289]	giv[289]	_	_
28-27	5162-5167	after	event[289]	giv[289]	_	_
28-28	5168-5187	phosphatidylcholine	substance|event[289]	giv|giv[289]	_	_
28-29	5188-5194	intake	event[289]	giv[289]	_	_
28-30	5195-5196	,	_	_	_	_
28-31	5197-5202	where	_	_	_	_
28-32	5203-5209	levels	abstract	giv	_	_
28-33	5210-5218	remained	_	_	_	_
28-34	5219-5227	elevated	_	_	_	_
28-35	5228-5231	for	_	_	_	_
28-36	5232-5234	12	quantity	giv	_	_
28-37	5235-5237	h.	quantity	new	_	_
